Thor Medical ASA (OSL:TRMED)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.73B |
| Revenue (ttm) | 839.00K |
| Net Income (ttm) | -58.01M |
| Shares Out | 361.38M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,268,075 |
| Average Volume | 2,678,889 |
| Open | 4.795 |
| Previous Close | 4.790 |
| Day's Range | 4.720 - 4.845 |
| 52-Week Range | 2.230 - 5.730 |
| Beta | -0.21 |
| RSI | 47.96 |
| Earnings Date | Aug 28, 2026 |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway. [Read more]
Financial Performance
Financial StatementsNews
Thor Medical ASA Earnings Call Transcript: H2 2025
AlphaOne remains on track for Q3 2025 production, supported by a NOK 850 million order backlog and strong market demand. The company is fully funded through ramp-up, with initial revenues validating technology and a clear path to profitability by 2027.
Thor Medical ASA Earnings Call Transcript: H1 2025
First commercial sales and major strategic agreements validate technology and market position. AlphaOne plant is fully funded, on schedule for 2026, and capacity was expanded by 40% after a successful capital raise. Revenue potential is strong, with a NOK 770 million order backlog and ambitious growth plans.
Thor Medical ASA Earnings Call Transcript: H2 2024
Transitioned from pilot to commercial phase with Alpha One fully funded and construction set to begin. Secured key sales agreements, validated technology, and positioned to meet surging demand in a rapidly growing radiopharmaceuticals market.
Thor Medical ASA Transcript: Capital Markets Update 2024
The company aims to become a leading supplier of lead-212 for targeted alpha therapies, leveraging a proprietary, scalable, and environmentally friendly production process. With a $1 billion revenue ambition and global expansion plans, it is positioned to address the growing demand for radiopharmaceuticals and support the shift toward alpha-based cancer treatments.
Thor Medical ASA Earnings Call Transcript: H1 2024
Leadership transition and strategic focus on radiopharmaceuticals position the company for growth, with a pilot plant nearing completion and Fast Track scale-up planned. Financials show a loss but sufficient funding for current operations, while market conditions remain highly favorable.